Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. Read more >>

Inside the small Norwood biotech that’s making investors swoon

The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers.
Investors in Corbus Pharmaceuticals don’t much seem to mind. The 3-year-old company, situated some 25 miles south of Cambridge and the bustling biotech hub of Kendall Square, has seen its stock price increase more than 400 percent since March 2016, putting […]

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression […]

Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8 at 10:40 a.m. ET in Boston, MA. Read more >>